ESMO 2023 | Minimizing the severity of treatment toxicities in oncology

Lazar Popovic, MD, PhD, University of Novi Sad, Novi Sad, Serbia, highlights the importance of properly identifying and tailoring treatment to specific patients; for example, considering dose alterations in frail patients. Dr Popovic states it is necessary to educate clinicians so that they are able to diagnose and treat life-threatening toxicities early such as interstitial lung disease in trastuzumab deruxtecan treatment by performing routine low-dose CTs even in asymptomatic patients. He states that it is very important to only allow patients who are fit enough to undergo CAR-T and to hospitalize patients upon any signs of cytokine release syndrome. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.